Anavex Life Sciences to Present at the Cowen 39th Annual Health Care Conference 2019

Anavex Life Sciences to Present at the Cowen 39th Annual Health Care Conference 2019   NEW YORK – March 6, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and…

Anavex Life Sciences Reports Publication of New Data that Show ANAVEX®2-73 Induces Cellular Recycling Process Linked to the Prevention and Treatment of Age-Associated Diseases

Anavex Life Sciences Reports Publication of New Data that Show ANAVEX®2-73 Induces Cellular Recycling Process Linked to the Prevention and Treatment of Age-Associated Diseases New preclinical data establishes ANAVEX®2-73 as a modulator of autophagy through Sigma-1 receptor activation, possibly needed for the prevention and treatment of neurodegenerative conditions including Alzheimer’s disease, Parkinson’s disease and ALS…

Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates

Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – February 7, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental…

Anavex Life Sciences to Present at the 2019 BIO CEO & Investor Conference

  Anavex Life Sciences to Present at the 2019 BIO CEO & Investor Conference NEW YORK – February 4, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other…

Anavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019

Anavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019 Conference Call and Webcast To be Held Thursday February 7, 2019 4:30pm Eastern Time NEW YORK – January 31, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for…

Anavex Life Sciences Announces the Appointment of Walter E Kaufmann, MD as Chief Medical Officer

Anavex Life Sciences Announces the Appointment of Walter E Kaufmann, MD as Chief Medical Officer  NEW YORK – January 2, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and…

Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update

Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – December 12, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases…

Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018

Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018   Conference Call and Webcast To be Held Wednesday, December 12, 2018at 4:30pm Eastern Time NEW YORK – December 10, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics…

Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)

Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)   NEW YORK – November 8, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease,…

First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)

  First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)   Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK – October 30, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics…